Fujimoto Naohiro
   Department   School of Medicine  Urology, Clinical Medical Sciences
Article types journal article
Language English
Peer review Peer reviewed
Title PD-L1 expression in papillary renal cell carcinoma.
Journal Formal name:BMC urology
Abbreviation:BMC Urol
ISSN code:14712490/14712490
Domestic / ForeginForegin
Volume, Issue, Page 17(1),8-8頁
Author and coauthor Motoshima Takanobu, Komohara Yoshihiro, Ma Chaoya, Dewi Arni Kusuma, Noguchi Hirotsugu, Yamada Sohsuke, Nakayama Toshiyuki, Kitada Shohei, Kawano Yoshiaki, Takahashi Wataru, Sugimoto Masaaki, Takeya Motohiro, Fujimoto Naohiro, Oda Yoshinao, Eto Masatoshi
Publication date 2017/01
Summary BACKGROUND:The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2).METHODS:In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC).RESULT:We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was not significantly correlated with any clinicopathological factor, including progression-free survival and overall survival. The frequency of PD-L1-positive cases was higher in type 2 (36%) than in type 1 (22%) pRCC; however, there was no significant difference in the percentages of score 0 cases (p value = 0.084 in Chi-square test). The frequency of high PD-L1 expression cases was higher in type 2 (23%) than in type 1 (11%), and the frequency of high PD-L1 expression cases was higher in grade 3/4 (21%) than in grade 1/2 (13%). However, no significant association was found between PD-L1 expression and all clinicopathological factors in pRCC.CONCLUSION:High expression of PD-L1 in cancer cells was potentially associated to highly histological grade of malignancy in pRCC. The evaluation of the PD-L1 protein might still be useful for predicting the efficacy of anti-cancer immunotherapy using immuno-checkpoint inhibitors, however, not be useful for predicting the clinical prognosis.
DOI 10.1186/s12894-016-0195-x
PMID 28086852